Angioslide

Company Overview

Snapshot

Founded in March 2005 by Amos Nahir and Eran Hirszowicz, Angioslide operated with 11–50 employees. The company raised a total of $33.15M across 7 funding rounds from 9 investors.

Business overview

Angioslide develops cost-effective products for emboli management during vascular interventions, primarily serving the healthcare sector. The company's core product, PROTEUS, is an FDA-cleared device designed to capture and remove embolic particles dislodged during peripheral artery interventions. Operating within the Health Tech & Life Sciences sector, specifically Medical Devices and Medical Treatment & Therapeutics, Angioslide's technology functions similarly to an angioplasty balloon but incorporates a single-use suction mechanism for debris containment and removal. The company's products are utilized by surgeons and hospitals in vascular surgery across markets including the United States and Europe.

Company Intelligence Q&A

What is Angioslide's primary product?

Angioslide's primary product is PROTEUS, an FDA-cleared device for embolic capture angioplasty, designed to capture and remove embolic particles during vascular interventions in peripheral arteries.

When did Angioslide announce the European launch of its 300 mm long device?

In September 2011, Angioslide announced the European launch of its new 300 mm long device, which allows for the treatment of the entire Superficial Femoral Artery (SFA) with a single device.

When did Angioslide receive FDA clearance for its PROTEUS device for below-the-knee use?

In May 2012, Angioslide announced FDA 510(K) clearance for its PROTEUS device for below-the-knee applications.

When was Angioslide named one of Israel's top ten most promising startups?

In November 2011, Angioslide was named one of Israel's top ten most promising startups for that year.